AMG 151 (ARRY-403), a novel glucokinase activator, decreases fasting and postprandial glycaemia in patients with type 2 diabetes.

Katz, L; Manamley, N; Snyder, W J; Dodds, M; Agafonova, N; Sierra-Johnson, J; Cruz, M; Kaur, P; Mudaliar, S; Raskin, P; Kewalramani, R; Pellacani, A

Katz, L; Manamley, N; Snyder, W J; Dodds, M; Agafonova, N; Sierra-Johnson, J; Cruz, M; Kaur, P; Mudaliar, S; Raskin, P; Kewalramani, R; Pellacani, A.

Affiliation

Katz L; Amgen Inc., Thousand Oaks, CA, USA.
Manamley N; Amgen Ltd, Cambridge, UK.
Snyder WJ; Amgen Inc., Thousand Oaks, CA, USA.
Dodds M; Amgen Inc., Seattle, WA, USA.
Agafonova N; Amgen Inc., Thousand Oaks, CA, USA.
Sierra-Johnson J; Amgen Inc., Thousand Oaks, CA, USA.
Cruz M; Amgen Inc., Thousand Oaks, CA, USA.
Kaur P; Amgen Inc., Thousand Oaks, CA, USA.
Mudaliar S; Center for Metabolic Research, Veterans Administration San Diego Healthcare System, San Diego, CA, USA.
Raskin P; University of Texas Southwestern Medical Center, Dallas, TX, USA.
Kewalramani R; Amgen Inc., Thousand Oaks, CA, USA.
Pellacani A; Amgen Inc., Thousand Oaks, CA, USA.

Diabetes Obes Metab ; 18(2): 191-5, 2016 Feb.

Article in En | MEDLINE | ID: mdl-26434934

Subject(s)

Aminopyridines/administration & dosage; Diabetes Mellitus, Type 2/drug therapy; Drugs, Investigational/administration & dosage; Enzyme Activators/administration & dosage; Glucokinase/metabolism; Hyperglycemia/prevention & control; Hypoglycemia/prevention & control; Hypoglycemic Agents/administration & dosage; Thiadiazoles/administration & dosage; Adult; Aminopyridines/adverse effects; Aminopyridines/therapeutic use; Blood Glucose/analysis; Diabetes Mellitus, Type 2/blood; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drugs, Investigational/adverse effects; Drugs, Investigational/therapeutic use; Enzyme Activators/adverse effects; Enzyme Activators/therapeutic use; Follow-Up Studies; Glucokinase/chemistry; Glycated Hemoglobin/analysis; Headache/chemically induced; Headache/epidemiology; Humans; Hyperglycemia/epidemiology; Hypertriglyceridemia/chemically induced; Hypertriglyceridemia/epidemiology; Hypoglycemia/chemically induced; Hypoglycemia/epidemiology; Hypoglycemic Agents/adverse effects; Hypoglycemic Agents/therapeutic use; Incidence; Least-Squares Analysis; Postprandial Period; Thiadiazoles/adverse effects; Thiadiazoles/therapeutic use; Triglycerides/blood

Key words

antidiabetic drug; clinical trial; dose-response relationship; glucokinase activator; type 2 diabetes

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Thiadiazoles / Drugs, Investigational / Enzyme Activators / Diabetes Mellitus, Type 2 / Glucokinase / Aminopyridines / Hyperglycemia / Hypoglycemia / Hypoglycemic Agents Type of study: Clinical_trials / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Language: En Journal: Diabetes Obes Metab Journal subject: ENDOCRINOLOGIA / METABOLISMO Year: 2016 Document type: Article Affiliation country: United States Country of publication: United kingdom

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google